PTGS2 and breast cancer: Four of these studies showed statistically significant overexpression of COX-2 in BC tissues compared to that in benign tissues of breast, and potential clinical use of COX-2 in prognosis prediction.17-20 These results are consistent with our report that addressed a significant increase (p=0.034).